Dimension entities report 6.5M shared GLUE shares
Monte Rosa Therapeutics (common stock) filing a Schedule 13G/A (Amendment No. 2) reports beneficial ownership by Dimension-related entities and affiliated individuals.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Monte Rosa Therapeutics (common stock) filing a Schedule 13G/A (Amendment No. 2) reports beneficial ownership by Dimension-related entities and affiliated individuals. The cover pages show shared voting and dispositive power over 6,513,765 shares for several reporting persons and 5,663,265 and 850,500 shares held directly by Dimension Capital I and Dimension Capital II, respectively. The percentages use a baseline of 80,015,667 shares outstanding as of March 2, 2026.
Insights
Holds and shared control by Dimension funds and affiliated principals disclosed.
Schedule 13G/A lists shared voting and dispositive power over specific share counts: 6,513,765, 5,663,265, and 850,500. The filing attributes ownership across fund entities and GP/management structures, consistent with pooled investment voting arrangements.
Key dependency is the 80,015,667 shares outstanding anchor used to compute reported percentages. Subsequent disclosures would show whether these holdings change.
Disclosure clarifies beneficial owners and reporting relationships for investor transparency.
The filing names individuals (Adam Goulburn, Zavain Dar, Nan Li) and entities (Dimension Management, Dimension Capital I/II and GP entities) and provides a business address. It explains the advisory/GP relationships that produce shared power metrics.
For investors, the filing documents ownership scale (single-figure percentages) using the issuer's reported outstanding shares as of March 2, 2026.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficial ownership financial
General partner (GP) corporate
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Dimension Capital I hold in Monte Rosa Therapeutics (GLUE)?
Who are the individuals listed on the Schedule 13G/A for GLUE?
Does the Schedule 13G/A indicate sole voting power for the reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.